Pozelimab

帕泽利单抗

Report date: 2026/02/13 20:01:31

Base Information

Drug NamePozelimab
Drug Alias NamePozelimab-bbfgVEOPOZREGN-3918
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalGeographic AtrophyProtein-Losing Enteropathies +[4] 
Global Approved IndicationsProtein-Losing Enteropathies
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/18
Country/TerritoryBelgiumCanadaUnited States +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalGeographic AtrophyProtein-Losing Enteropathies +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A